| Name | Title | Contact Details |
|---|
Dyadic uses its proprietary C1 platform technology to discover and develop novel genes and other biological products from eukaryotic organisms found in the full spectrum of the earth’s biodiversity. Once useful genes are isolated, Dyadic uses its integrated platform to manufacture specific proteins, doing so more rapidly and efficiently — and with a much higher rate of success than existing gene discovery systems. Dyadic leverages its proprietary technology platform to discover novel genes and biological products for use by its strategic partners, and to further its own R&D efforts. Dyadic seeks strategic alliances with major leaders in the agricultural, bioenergy, industrial enzyme, chemical and biopharmaceutical industries that have in-house genomic capabilities. Dyadic will also collaborate with companies whose genomic capabilities are limited, discovering and expressing biological materials for these strategic partners. In addition, Dyadic, using these proprietary systems, will continue to commercialize enzymes for use in targeted markets, including the animal nutrition, detergent, ethanol, pulp and paper, biopharmaceutical, starch and textile industries. Dyadic expects to generate revenue from its product sales, revenue generated from research and development services and funding as well as revenue generated from licensing and other strategic collaborations in the form of milestone and royalty payments.
Earli has been funded by Andreessen Horowitz`s Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast`s prime biotech hub in South San Francisco.
Ventria BioScience is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Celator Pharmaceuticals is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Denali Therapeutics Inc. (“Denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).